Based on objective and critical appraisal of the literature on potential adverse effects of statins, the EAS Consensus Panel concludes that statin treatment is remarkably safe.
A multidisciplinary ESC Task Force aimed to give as much practical advice as possible on the most appropriate management and therapy for each of the subtypes of syncope, although trial evidence is scarce.
The potential incremental benefit of PCSK9 inhibition varies a lot among patients with stable CAD, with the greatest benefit observed in younger patients with highest risk factor burden and high LCL-c levels.
In a large prospective study, risk of all-cause mortality increases above 100 g alcohol per week, and positive associations with alcohol intake were seen mostly for stroke and HF, as opposed to MI.
This document covers five topics that help cardiologists understand what is important when treating patients with diabetes, and which risks these patients face. Download your free copy.
In a data-driven cluster analysis of 6 variables in adult patients with newly diagnosed diabetes, 5 categories of patients were identified with different characteristics and risks of complications.
A large pan-European study shows that overweight and obesity are associated with higher risk of CHD, even if the person does not have metabolic syndrome.
Improving adherence to healthy dietary patterns could attenuate the association between genetic predisposition and BMI and weight increases, particularly in individuals at high genetic risk.
Population-based study shows that women with GDM are over 20 times more likely to develop T2DM and have an almost doubled risk of hypertension, and 2.8-fold higher risk of IHD, compared with control.
Statin eligibility differs substantially in the 5 major guidelines, and this impacts on the potential prevention of ASCVD events, which is a function of the number of eligible persons for statin therapy.
Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.
In a prospective community-based cohort, Lp(a) ≥50 mg/dL was associated with higher stroke risk in those without AF, but not in those with AF, nor with an elevated risk of AF.